Changes in hepatic protein expression in spontaneously hypertensive rats suggest early stages of non-alcoholic fatty liver disease

Journal of Proteomics

Volumn 75, Issue 6, 2012, Pages 1752-1763

  Svoboda, Devon S ^a   Kawaja, Michael D ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Haptoglobin; Liver; Oxidative stress; Proteomics; QDPR; SHR; Sulfite oxidase

Indexed keywords

CARBOXYLESTERASE; GLUTATHIONE TRANSFERASE; HAPTOGLOBIN; PROTEOME; SULFITE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; ISOELECTRIC FOCUSING; LIPID METABOLISM; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WISTAR KYOTO RAT;

ANIMALS; FATTY LIVER; GLUTATHIONE TRANSFERASE; HYPERTENSION; LIVER; MALE; OXIDATIVE STRESS; OXIDOREDUCTASES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SULFITE OXIDASE;

RATTUS;

EID: 84857654021     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.12.011     Document Type: Article

References (77)

1. Guyenet P.G. The sympathetic control of blood pressure. Nat Rev 2006, 7:335-346.
2. Shimamoto K., Ura N. Mechanisms of insulin resistance in hypertensive rats. Clin Exp Hypertens 2006, 28(6):543-552.
3. Chueng O. Hypertension as part of the metabolic syndrome. J Hum Hypertens 2008, 22:871-874.
4. Yanai H., Tomono Y., Ito K., Furutani N., Yoshida H., Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J 2008, 7:10.
5. Cuspidi C., Valerio C., Giudici V., Negri F., Sala C., Zanchetti A., et al. Metabolic syndrome and multiple organ damage in essential hypertension. Blood Press 2008, 17(4):195-203.
6. Fallo F., Dalla Pozza A., Sonino N., Lupia M., Tona F., Federspil G., et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009, 19(9):646-653.
7. Pravenec M., Zídek V., Landa V., Simáková M., Mlejnek P., Kazdová L., et al. Genetic analysis of "metabolic syndrome" in the spontaneously hypertensive rat. Physiol Res 2004, 53(Suppl 1):S15-S22.
8. Lonardo A., Lombardini S., Ricchi M., Scaglioni F., Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005, 22(Suppl 2):64-70.
9. Cheung O., Sanyal A.J. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin Liver Dis 2008, 28(4):351-359.
10. Wei Y., Rector R.S., Thyfault J.P., Ibdah J.A. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008, 14(2):193-199.
11. Paschos P., Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009, 13(1):9-19.
12. Mehta K., Van Thiel D.H., Shah N., Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002, 60(9):289-293.
13. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007, 24(1):1-6.
14. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51(11):1947-1953.
15. Targher G., Bertolini L., Padovani R., Rodella S., Zoppini G., Zenari L., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29(6):1325-1330.
16. Yahia D.A., Madani S., Prost E., Prost J., Bouchenak M., Belleville J. Tissue antioxidant status differs in spontaneously hypertensive rats fed fish protein or casein. J Nutr 2003, 133(2):479-482.
17. Gómez-Amores L., Mate A., Revilla E., Santa-María C., Vázquez C.M. Antioxidant activity of propionyl-l-carnitine in liver and heart of spontaneously hypertensive rats. Life Sci 2006, 78(17):1945-1952.
18. Oh K.S., Han W., Wang M.H., Lee B.H. The effects of chronic treatment with Morus bombycis KOIDZUMI in spontaneously hypertensive rats. Biol Pharm Bull 2007, 30(7):1278-1283.
19. Oh K.S., Ryu S.Y., Oh B.K., Seo H.W., Kim Y.S., Lee B.H. Antihypertensive, vasorelaxant, and antioxidant effect of root bark of Ulmus macrocarpa. Biol Pharm Bull 2008, 31(11):2090-2096.
20. Tada Y., Kagota S., Kubota Y., Nejime N., Nakamura K., Kunitomo M., et al. Long-term feeding of Ginkgo biloba extract impairs peripheral circulation and hepatic function in aged spontaneously hypertensive rats. Biol Pharm Bull 2008, 31(1):68-72.
21. Ueno T., Fukuda N., Nagase H., Tsunemi A., Tahira K., Matsumoto T., et al. Atherogenic dyslipidemia and altered hepatic gene expression in SHRSP.Z-Leprfa/IzmDmcr rats. Int J Mol Med 2009, 23(3):313-320.
22. Bonen A., Han X.X., Tandon N.N., Glatz J.F., Lally J., Snook L.A., et al. FAT/CD36 expression is not ablated in spontaneously hypertensive rats. J Lipid Res 2008, 50(4):740-748.
23. Rodríguez A., Catalán V., Becerril S., Gil M.J., Mugueta C., Gómez-Ambrosi J., et al. Impaired adiponectin-AMPK signalling in insulin-sensitive tissues of hypertensive rats. Life Sci 2008, 83(15-16):540-549.
24. Kitts D.D., Yuan Y.V., Godin D.V. Plasma and lipoprotein lipid composition and hepatic antioxidant status in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Can J Physiol Pharmacol 1998, 76(2):202-209.
25. Yuan Y.V., Kitts D.D. Dietary (n-3) fat and cholesterol alter tissue antioxidant enzymes and susceptibility to oxidation in SHR and WKY rats. J Nutr 2003, 133(3):679-688.
26. Okamoto K., Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963, 27:282-293.
27. Scott T.M., Pang S.C. The correlation between the development of sympathetic innervation and the development of medial hypertrophy in jejunal arteries in normotensive and spontaneously hypertensive rats. J Auton Nerv Syst 1983, 8(1):25-32.
28. Intengan H.D., Thibault G., Li J.S., Schiffrin E.L. Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999, 100(22):2267-2275.
29. Videla L.A., Rodrigo R., Araya J., Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004, 37(9):1499-1507.
30. Videla L.A., Rodrigo R., Orellana M., Fernandez V., Tapia G., Quiñones L., et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004, 106(3):261-268.
31. Albano E., Mottaran E., Occhino G., Reale E., Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005, 22(Suppl 2):71-73.
32. Graham D.R., Elliott S.T., Van Eyk J.E. Broad-based proteomic strategies: a practical guide to proteomics and functional screening. J Physiol 2005, 563(Pt 1):1-9.
33. Shevchenko A., Jensen O., Podtelejnikov A., Sagliocco F., Wilm M., Vorm O., et al. Linking genome and proteome by mass spectrometry: large-scale identification of yeast proteins from two dimensional gels. Proc Natl Acad Sci U S A 1996, 93(25):14440-14445.
34. Candiano G., Bruschi M., Musante L., Santucci L., Ghiggeri G.M., Carnemolla B., et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004, 25(9):1327-1333.
35. McDonald T., Scott S., Kane K., Kawaja M. Proteomic assessment of sympathetic ganglia from adult mice that possess null mutations of ExonIII or ExonIV in the p75 neurotrophin receptor gene. Brain Res 2008, 1253:1-14.
36. Sheehan D., Meade G., Foley V.M., Dowd C.A. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem J 2001, 360(Pt 1):1-16.
37. Chalupsky K., Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2005, 102(25):9056-9061.
38. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005, 45:51-88.
39. Herken E.N., Kocamaz E., Erel O., Celik H., Kucukatay V. Effect of sulfite treatment on total antioxidant capacity, total oxidant status, lipid hydroperoxide, and total free sulfydryl groups contents in normal and sulfite oxidase-deficient rat plasma. Cell Biol Toxicol 2008, 10.1007/s10565-008-9089-3.
40. Suematsu M., Suzuki H., Delano F.A., Schmid-Schönbein G.W. The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation 2002, 9(4):259-276.
41. Nabha L., Garbern J.C., Buller C.L., Charpie J.R. Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats. Clin Exp Hypertens 2005, 27(1):71-82.
42. Tanito M., Nakamura H., Kwon Y.W., Teratani A., Masutani H., Shioji K., et al. Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 2004, 6(1):89-97.
43. Mindnich R., Möller G., Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2004, 218(1-2):7-20.
44. Fortepiani L.A., Reckelhoff J.F. Treatment with tetrahydrobiopterin reduces blood pressure in male SHR by reducing testosterone synthesis. Am J Physiol Regul Integr Comp Physiol 2005, 288(3):R733-R736.
45. Feng C., Tollin G., Enemark J.H. Sulfite oxidizing enzymes. Biochim Biophys Acta 2008, 1774(5):527-539.
46. Karakas E., Wilson H.L., Graf T.N., Xiang S., Jaramillo-Busquets S., Rajagopalan K.V., et al. Structural insights into sulfite oxidase deficiency. J Biol Chem 2005, 280(39):33506-33515.
47. Chiarani F., Bavaresco C.S., Dutra-Filho C.S., Netto C.A., Wyse A.T. Sulfite increases lipoperoxidation and decreases the activity of catalase in brain of rats. Metab Brain Dis 2008, 23(1):123-132.
48. Niknahad H., O'Brien P.J. Mechanism of sulfite cytotoxicity in isolated rat hepatocytes. Chem Biol Interact 2008, 174(3):147-154.
49. Higashi N., Senoo H. Distribution of vitamin A-storing lipid droplets in hepatic stellate cells in liver lobules-a comparative study. Anat Rec A Discov Mol Cell Evol Biol 2003, 271(1):240-248.
50. Wu J., Zern M.A. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000, 35(9):665-672.
51. Muriel P. Role of free radicals in liver diseases. Hepatol Int 2009, [Epub ahead of print].
52. Asleh R., Levy A.P. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005, 1(1):19-28.
53. Dayan L., Levy A.P., Blum S., Miller-Lotan R., Melman U., Alshiek J., et al. Haptoglobin genotype and endothelial function in diabetes mellitus: a pilot study. Eur J Appl Physiol 2009, 106(4):639-644.
54. Hübscher S.G. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006, 49(5):450-465.
55. Vasdev N., Kakati A.G., Saigal S., Nayak N.C. Spectrum of histological features in non-alcoholic fatty liver disease. Natl Med J India 2007, 20(6):282-287.
56. Scriver C.R. Science, medicine and phenylketonuria. Acta Paediatr 1994, 407:11-18. Suppl.
57. Hong H.J., Hsiao G., Cheng T.H., Yen M.H. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 2001, 38(5):1044-1048.
58. Lee C.K., Han J.S., Won K.J., Jung S.H., Park H.J., Lee H.M., et al. Diminished expression of dihydropteridine reductase is a potent biomarker for hypertensive vessels. Proteomics 2009, 9(21):4851-4858.
59. Noguchi K., Hamadate N., Matsuzaki T., Sakanashi M., Nakasone J., Sakanashi M., et al. Improvement of impaired endothelial function by tetrahydrobiopterin in stroke-prone spontaneously hypertensive rats. Eur J Pharmacol 2010, 631(1-3):28-35.
60. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003, 111(8):1201-1209.
61. Alp N.J., Channon K.M. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24(3):413-420.
62. Schulz E., Jansen T., Wenzel P., Daiber A., Münzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008, 10(6):1115-1126.
63. Sullivan J.C., Sasser J.M., Pollock J.S. Sexual dimorphism in oxidant status in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2006, 292(2):R764-R768.
64. Kienitz T., Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res 2008, 31(2):71-79.
65. Jin HF D.U.S.X., Zhao X., Zhang S.Q., Tian Y., Bu D.F., Tang C.S., et al. Significance of endogenous sulfur dioxide in the regulation of cardiovascular system (Chinese). Beijing Da Xue Xue Bao 2007, 39(4):423-425.
66. Langlois M.R., Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996, 42(10):1589-1600.
67. Wu L., Juurlink B.H. The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2001, 19(10):1819-1825.
68. Izzotti A., Cartiglia C., Lewtas J., De Flora S. Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype. FASEB J 2001, 15(3):752-757.
69. Schneider J., Bernges U., Philipp M., Woitowitz H.J. GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking. Cancer Lett 2004, 208(1):65-74.
70. Fearnley I.M., Finel M., Skehel J.M., Walker J.E. NADH:ubiquinone oxidoreductase from bovine heart mitochondria. cDNA sequences of the import precursors of the nuclear-encoded 39kDa and 42kDa subunits. Biochem J 1991, 278(Pt 3):821-829.
71. Remacle C., Barbieri M.R., Cardol P., Hamel P.P. Eukaryotic complex I: functional diversity and experimental systems to unravel the assembly process. Mol Genet Genomics 2008, 280(2):93-110.
72. Schulenberg B., Aggeler R., Beechem J.M., Capaldi R.A., Patton W.F. Analysis of steady-state protein phosphorylation in mitochondria using a novel fluorescent phosphosensor dye. J Biol Chem 2003, 278(29):27251-27255.
73. Jin X., Xia L., Wang L.S., Shi J.Z., Zheng Y., Chen W.L., et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics 2006, 6(6):1948-1956.
74. Schilling B., Aggeler R., Schulenberg B., Murray J., Row R.H., Capaldi R.A., et al. Mass spectrometric identification of a novel phosphorylation site in subunit NDUFA10 of bovine mitochondrial complex I. FEBS Lett 2005, 579(11):2485-2490.
75. Muñoz J., Fernández-Irigoyen J., Santamaría E., Parbel A., Obeso J., Corrales F.J. Mass spectrometric characterization of mitochondrial complex I NDUFA10 variants. Proteomics 2008, 8(9):1898-1908.
76. Meng C., Jin X., Xia L., Shen S.M., Wang X.L., Cai J., et al. Alterations of mitochondrial enzymes contribute to cardiac hypertrophy before hypertension development in spontaneously hypertensive rats. J Proteome Res 2008, 8(5):2463-2475.
77. Jüllig M., Hickey A.J., Chai C.C., Skea G.L., Middleditch M.J., Costa S., et al. Is the failing heart out of fuel or a worn engine running rich? A study of mitochondria in old spontaneously hypertensive rats. Proteomics 2008, 8(12):2556-2572.